Antidepressant selection remains largely trial-and-error. Pharmacometabolomics, pharmacogenomics and AI-supported interpretation may help build more informed treatment-selection frameworks.
Major Depressive Disorder remains one of the clearest examples of a clinical area where treatment selection often depends on trial-and-error.
By integrating clinical characterization, pharmacometabolomics, pharmacogenomics and machine-learning-assisted interpretation, precision psychiatry can move toward more biologically informed treatment decisions.
Imperion’s role in this field focuses on molecular validation, integrated data interpretation, biostatistical analysis and AI-oriented predictive framework development.